Cyclophilin A interacts with diverse lentiviral capsids by Lin, Tsai-Yu & Emerman, Michael
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Retrovirology
Open Access Research
Cyclophilin A interacts with diverse lentiviral capsids
Tsai-Yu Lin1 and Michael Emerman*1,2
Address: 1Pathobiology Graduate Program, University of Washington, Seattle, WA 98195, USA and 2Division of Human Biology, Fred Hutchinson 
Cancer Research Center, Seattle, WA 98109, USA
Email: Tsai-Yu Lin - linty@u.washington.edu; Michael Emerman* - memerman@fhcrc.org
* Corresponding author    
Abstract
Background: The capsid (CA) protein of HIV-1 binds with high affinity to the host protein
cyclophilin A (CypA). This binding positively affects some early stage of the viral life-cycle because
prevention of binding either by drugs that occupy that active site of cyclophilin A, by mutation in
HIV-1 CA, or RNAi that knocks down intracellular CypA level diminishes viral infectivity. The
closely related lentivirus, SIVcpz also binds CypA, but it was thought that this interaction was
limited to the HIV-1/SIVcpz lineage because other retroviruses failed to interact with CypA in a
yeast two-hybrid assay.
Results: We find that diverse lentiviruses, FIV and SIVagmTAN also bind to CypA. Mutagenesis of
FIV CA showed that an amino acid that is in a homologous position to the proline at amino acid 90
of HIV-1 CA is essential for FIV interactions with CypA.
Conclusion: These results demonstrate that CypA binding to lentiviruses is more widespread
than previously thought and suggest that this interaction is evolutionarily important for lentiviral
infection.
Background
Cyclophilin A (CypA) is a highly conserved peptidyl pro-
lyl isomerase (PPIA) that is incorporated into HIV-1 viri-
ons and plays a yet undefined role in the early stages of
viral replication in some cell types [1-3]. CypA interacts
with HIV-1 by virtue of a direct binding between residues
in a loop between the fourth and fifth alpha-helices of the
capsid (CA) protein of HIV-1 and the active site of CypA
[4-6]. Cyclosporin A (CsA), an immunosuppressive drug,
binds to the same region of binding groove of CypA and
disrupts the CypA/CA interaction which leads to an atten-
uation of wild type HIV-1 infectivity by 2–5 fold in T cells
[7-9]. Although CypA can bind to viral CA in the producer
cell during viral assembly, it is CypA in the newly infected
target cells that is important for infectivity rather than the
CypA that is present in the producer cell [8-11]
Tripartite motif 5 isoform alpha (Trim5α) proteins also
bind to retroviral CA early after viral entry, and can have a
negative effect on the viral lifecycle by accelerating the
viral core uncoating or CA degradation [12-15]. Trim5α
contains a C-terminal B30.2 domain that recognizes retro-
viral CA and restricts viral replication in a species-specific
manner [12,16]. The resistance of cells from the owl mon-
key (Aotus trivirgatus) to HIV-1 infection is due to the pres-
ence of a natural fusion protein in this species, called
TrimCyp, in which the B30.2 recognition domain of
Trim5α was replaced by the CypA gene [17,18]. CypA is
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important for the activities of some Trim5α alleles
[19,20].
The CypA/CA interaction was initially identified by two-
hybrid analysis in yeast [1,5]. In those studies, it was
reported that only HIV-1 and the closely related SIVcpz
encoded Gag proteins (which are cleaved by viral protease
to generate CA during maturation) that could interact
with CypA, while the Gag proteins from HIV-2, SIVmac,
SIVs from African green monkeys-Sabaeus (SIVagmSAB),
feline immunodeficiency viruses (FIV), and Mason-Pfizer
monkey viruses (MPMV) failed to interact with CypA in
this assay [5]. Furthermore, incorporation of CypA into
virions was detected in HIV-1 and SIVcpz, but not in HIV-
2, SIVmac, SIVagm-Grivet (SIVagmGRI), and murine
leukemia viruses (MLV) [5]. However, here we show that
the CypA/CA interaction is not unique to HIV-1/SIVcpz.
By both genetic and biochemical experiments we show
that FIV can bind CypA and its replication is affected by
this interaction to the same extent as HIV-1. Moreover, we
have identified an amino acid that is essential for FIV CA
interaction with CypA that is in a nearly identical context
to an amino acid necessary for the interaction of HIV-1 CA
with CypA. Finally, we show that SIVagm-Tantalus (SIVag-
mTAN) is restricted by TrimCyp, strongly suggesting that
this viral CA also interacts with CypA. While these studies
were in progress, two other groups also provided evidence
that FIV and SIVagm are both susceptible to the TrimCyp
restriction in a CsA sensitive manner [21,22]. Together,
these results demonstrate that lentiviral interactions with
CypA are more conserved than had been previously
assumed and suggest that CypA/CA interactions play an
evolutionarily conserved role in the life cycle of many len-
tiviruses.
Results
FIV CA interacts with CypA
We began this study by looking at the pattern of restric-
tion effect of Trim5α isolated from diverse primate species
with a panel of different retroviruses. Remarkably, we
found that HIV-1 and FIV had an identical pattern of
restriction in that both were strongly restricted by rhesus
Trim5α, had slight sensitivity to human and Tamarin
Trim5α, and were resistant to Titi Trim5α (data not
shown). Similar data was also reported by another group
[23]. Because Trim5α restriction, like the CypA interac-
tion, is dictated by CA, this led us to examine if FIV is also
similar to HIV-1 in its interaction with CypA.
The TrimCyp protein from owl monkeys strongly restricts
HIV-1 because the C-terminal CypA portion of the protein
binds to HIV-1 CA, while the N-terminal portion of the
protein leads to premature uncoating or degradation of
incoming virions [13,14,17,18]. We therefore asked
whether FIV is also sensitive to TrimCyp restriction as an
indirect measure of CA-CypA recognition. Cells express-
ing TrimCyp were generated and infected with VSV-G
pseudotyped wild-type HIV-1, a HIV-1 G89V mutant (CA
with a G89V mutation does not bind CypA [2]), and FIV
(Fig. 1). Infections were done in the presence or absence
of CsA to verify the dependence of the restriction on CypA
function. Because infections were done with viruses that
encode GFP (see Methods), the number of infected cells
could be directly analyzed by flow cytometry (Fig. 1).
Consistent with previous reports [17,18], HIV-1 is sensi-
tive to TrimCyp restriction and the restriction can be neu-
tralized by treatment of cells with CsA (Fig. 1A), while the
negative control, the HIV-1 G89V mutant, is not restricted
by TrimCyp (Fig. 1B). We found that FIV behaves similar
to HIV-1 in that it was restricted by TrimCyp, and this
restriction is reversed by CsA (Fig. 1C).
These results with TrimCyp suggested that FIV does
indeed interact with CypA. In order to test this directly, we
used an assay to biochemically detect binding of CypA to
FIV CA (Fig. 2). Thus, 293T cells were transiently trans-
fected with a plasmid that expressed a fusion protein
between GST and human CypA (GST-CypA) or with GST
alone. Cell lysates were then incubated with glutathione
beads to partially purify the GST proteins from the cell
extracts. After washing to remove unbound proteins, the
beads were incubated with FIV virions, and the GST-
bound proteins were run on SDS-PAGE gels and blotted
with anti-CA antibodies. HIV-1 WT and G89V were used
as the positive and negative controls for this assay, respec-
tively. HIV-1 wild type associates with CypA because it is
pulled down by the GST-CypA fusion protein, whereas the
HIV-1 G89V mutant does not bind to GST-CypA (data not
shown). On the other hand, FIV behaves similar to HIV in
that partially purified GST-CypA, but not GST alone, is
able to bind FIV in vitro (Fig. 2A). This binding is dose-
dependent (adding more FIV virions increases the amount
of CA that is pulled-down, Fig. 2B, top), and is sensitive to
CsA (Fig. 2B, bottom). Thus, by both genetic (TrimCyp
restriction) and biochemical (GST-CypA pull-downs)
assays, we demonstrate that FIV, like HIV-1, interacts with
CypA.
Proline 90 on FIV capsid is an essential amino acid for 
Cyclophilin A binding
The glycine at position 89 and the proline at position 90
on HIV-1 capsid are the most critical target amino acids of
CypA binding [2]. Since we observed that FIV also inter-
acts with CypA, we next tried to identify if amino acids in
a similar region of CA of FIV are also critical for the CypA
recognition. By aligning the capsid amino acid sequence
of FIV with that of HIV-1, we noticed that FIV capsid con-
tains five prolines on the loop between the predicted
alpha-helices 4 and 5 (Fig. 3A). Each of these five proline
residues was individually mutated to alanine. In addition,Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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Infectivity of HIV-1 WT, G89V mutant and FIV under the TrimCyp restriction Figure 1
Infectivity of HIV-1 WT, G89V mutant and FIV under the TrimCyp restriction. CRFK and CRFK-TrimCyp cells 
were infected with HIV-1 wild-type (A), HIV-1 G89V (B), and FIV (C) in the presence or absence of CsA. The infected cells 
were analyzed by flow cytometry and the infectivity is presented as percentage of cells that were GFP+ (on a log scale).Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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Biochemical interaction of CypA and FIV CA Figure 2
Biochemical interaction of CypA and FIV CA. (A) GST-CypA or control GST fusion proteins were generated in 293T 
cells. After the incubation of the 293T cell lysates with glutathione beads, the beads were washed to remove unbound proteins, 
and then incubated with FIV virions. After removing unbound FIV virions by washing, beads were subjected to the SDS-PAGE 
and probed with anti-FIV CA antibodies for the detection of the interaction between CypA and FIV CA. (B) was conducted 
with the same experimental protocol for (A), but with different amounts of input FIV virions (serial dilution) in the presence or 
absence of 10 μM of CsA.Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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arginine at position 89 was also mutated to alanine
CypA/CA interaction in FIV WT and mutants Figure 3
CypA/CA interaction in FIV WT and mutants. (A) The CA amino acid sequence alignment of FIV with HIV-1. The pro-
line to alanine and the arginine to alanine mutations are in bold, and gaps are indicated with "-". (B) Infectivity of FIV wild type 
and mutants under the TrimCyp restriction. FIVs wild type and mutants were transduced to CRFK or CRFK-TrimCyp cells to 
test their sensitivity to TrimCyp restriction. The % GFP determined by flow cytometry is the readout of the infectivity. (C) 
GST-CypA pull-down of CA from wild type and mutant FIV. The upper panel shows 10% of input FIV virions used for the GST-
CypA pull-down assay, and the lower panel shows the CA pulled down by GST-CypA. FIV virions are detected by anti-FIV CA 
antibody.Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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because this position corresponds to the critical glycine at
position 89 in the HIV CA (Fig. 3A).
These constructs were then co-transfected to 293T cells
with VSV-G and GFP reporter plasmids to generate VSV-G
pseudotyped FIVs that were used to infect CRFK or CRFK-
TrimCyp cells. The infectivity of each virus was normal-
ized to give an amount of virus that resulted in about the
same number of infected CRFK cells. Similar to wild-type
FIV, the mutations P84A, P85A, P88A, P92A, and R89A
are also restricted by TrimCyp (Fig. 3B). Moreover, in each
case, the restriction by TrimCyp is abrogated by the addi-
tion of CsA. These data indicate that mutating each of
these residues did not destroy a functional interaction
between CypA and the viral CA. However, the P90A
mutant is not sensitive to the TrimCyp restriction and the
infectivity is not affected by the addition of CsA. This indi-
cates that amino acid P90 is critical for a functional inter-
action between FIV CA and CypA (Fig. 3B).
In addition to the TrimCyp assay, we also applied the
GST-CypA pull down assay to test the interaction of CypA
and FIV mutants. The FIV wild type and mutant virions
were incubated with the GST-CypA and the interactions
were analyzed by Western Blotting (Fig. 3C). Wild-type
FIV and other mutants are sensitive to the TrimCyp restric-
tion and are pulled down by the GST-CypA. On the other
hand, the P90A mutant, which is not sensitive to the Trim-
Cyp restriction, is also not pulled down by GST-CypA (Fig.
3C). These data demonstrate that amino acid P90 is a crit-
ical target for CypA binding to FIV CA.
CypA affects FIV infection
Previous reports showed that CsA decreases spreading
infections of FIV in cells and in animals [24,25]. However,
comparisons with HIV-1 were not done. It has been
shown that the infectivity of HIV-1 drops 2–5 fold when
the CypA/CA interaction is blocked by CsA in Jurkat T
cells in single-cycle infection experiments [7-9]. To exam-
ine the role of CypA in FIV infection in the same cell type,
Jurkat T cells were infected with VSV-G-pseudotyped FIV
in the presence or absence of CsA (Fig. 4). As expected, the
infectivity of wild type HIV-1 was reduced by the addition
of CsA (Fig. 4, top). We obtained reduced infections of FIV
in Jurkat cells relative to CRFK cells presumably due to
human Trim5α restriction of FIV [23]. However, similar to
HIV-1, the infectivity of FIV decreased further by 2–5 fold
when CsA was present during infection (Fig. 4, middle).
The P90A mutant of FIV which fails to bind cyclophilin A
(Fig. 3), in contrast, was not sensitive to CsA treatment
(Fig. 4, bottom). These results indicate that FIV, like HIV-
1, requires the endogenous cyclophilin A in target cells for
optimal infection.
SIVagmTAN also binds to CypA
We aligned the amino acids in the region between the
prediced alpha-helices 4 and 5 of CA from a number of
different lentiviruses, and noticed that SIVagmTAN, simi-
lar to FIV, has 5 prolines, and that the length of the SIVag-
mTAN loop (9 amino acids) is the same as HIV-1 (Fig.
5A). We therefore tested whether SIVagmTAN also inter-
acts with CypA using the TrimCyp assay (Fig. 5B). Consist-
ent with other reports [5,6], SIVmac, as a negative control,
is not sensitive to the TrimCyp. On the other hand, SIVag-
mTAN behaves like HIV-1 and FIV. The infectivity of
SIVagmTAN is strongly restricted by TrimCyp protein, and
the restriction can be counteracted by the treatment of
CsA (Fig. 5B). This result suggests that the CA of SIVag-
mTAN is also recognized by the CypA, and that the ability
of CypA to recognize lentiviral capsids is widespread,
although not universal, among lentiviruses.
Discussion
The CypA/CA interactions had originally been described
only for HIV-1 and SIVcpz [5]. Here, we show that this
phenotype is more widespread among lentiviruses
because both FIV and SIVagmTAN also interact with
CypA. Moreover, we identified an amino acid in FIV CA
that is critical for CypA binding that is in a similar posi-
tion in CA of HIV-1. Finally, we show that the CypA/CA
interaction is functionally significant for FIV replication.
It is not clear why a functional assay (Fig. 1) and a direct
binding assay (Fig. 2) detected the CypA/CA interaction in
FIV, whereas previous reports that looked for interactions
with a yeast-two hybrid assay or by expression of recom-
binant Gag and CypA in E. Coli did not [5]. It is possible
that the formation of mature viral core may be more
important for CypA recognition of FIV, or that subtle fold-
ing problems with FIV Gag was expressed in yeast and E.
Coli might have prevented binding. Nonetheless, the two
assays used here (TrimCyp restriction and GST-CypA pull
down) were conducted in mammalian cells and thus
more closely mimic the structure of CA found in natural
targets cells.
The finding that FIV and SIVagmTAN also bind host CypA
demonstrates that the CypA/CA interaction is a more wide
spread phenotype among lentiviruses than just the HIV-1/
SIVcpz lineage. At this point it is not possible to determine
if this property arose independently in three separate len-
tivirus lineages, or if an ancestral retrovirus was able to
bind CypA and then other lentiviruses (for example, SIV-
mac) each lost this ability. Although the latter possibility
is more parsimonious, it will be important to test a much
broader range of lentiviruses for CypA binding. It is also
possible that the ability of a lentivirus to bind CypA is evo-
lutionarily dynamic and changes upon adaptation to new
hosts.Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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The CypA-dependency of FIV Figure 4
The CypA-dependency of FIV. Jurkat T cells were infected with HIV-1 wild-type (A), FIV wild-type (B), and FIV P90A (C) in 
the presence or absence of 1.25 μM of CsA. All viruses were first normalized on CRFK cells and equivalent CRFK infectious 
units were used and are plotted on the X-axis. For example, the amount of virus that gave 20% GFP positive cells on CRFK 
cells is 0.2 on the X-axis. The infected Jurkat cells were analyzed by flow cytometry and the infectivity is presented as % GFP+ 
cells.Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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CypA/CA interaction in SIVmac, HIV-1, and SIVagmTAN Figure 5
CypA/CA interaction in SIVmac, HIV-1, and SIVagmTAN. (A) Sequence alignment of HIV-1 and other lentiviruses. 
The amino acid sequences of the loop between α helices 4 and 5 were aligned with HIV-1. Prolines are in bold, and gaps are 
indicated as "-". (B) Infectivity of HIV-1, SIVmac, and SIVagmTAN under the TrimCyp restriction. CRFK or CRFK-TrimCyp 
cells were infected with HIV-1-luc, SIVmac-luc, and SIVagmTan-luc, and the infectivity was determined by luminometer.Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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We determined that the proline at amino acid 90 on FIV
CA is critical for the interaction with CypA. This is similar
to the site on HIV-1 that binds CypA, suggesting the pro-
line in the middle of the loop is crucial for CypA recogni-
tion. However, the CA sequence alignment of SIVmac
with HIV-1 shows that SIVmac also possesses this corre-
sponding proline (Fig. 5A). The major difference of the
loop between the fourth and fifth alpha-helices in HIV-1
and SIVmac is its length. We applied the SWISS-MODEL
computer modelling to generate putative structure of CA
from SIVmac and SIVagmTAN based on the crystal struc-
ture of HIV-1 CA bound to CypA (PDB:1AK4). We found
that the CypA-binding loop of SIVagmTAN can be super-
imposed on the parallel loop of HIV-1 well, while the
loop of SIVmac is shorter than that of HIV-1 and is not
able to fit in the HIV-1 scale (Fig. 6). This suggests that in
addition to the proline at position 90 (based on HIV-1),
the length of the loop also contributes to the CypA bind-
ing. A shorter loop might not be able to insert into the
binding groove of CypA even though the target proline is
present in the middle of the loop. On the other hand,
Cyclophilin B (CypB), another member in the cyclophilin
family, was showed to interact with Gag proteins from
HIV-1 and SIVmac [1,2]. However, the CypB/Gag interac-
tion in both HIV-1 and SIVmac is not mediated by bind-
ing of CypB to the same loop that CypA recognizes. To our
knowledge, the CypB/Gag interaction has not been
reported to affect viral replication.
The exact role of CypA/CA interaction in HIV-1 life cycle
is still not clear. However, several groups have suggested
that CypA/CA interaction mediates the lentiviral suscepti-
bility to Trim5α restriction [17-19,26,27]. The discovery
of TrimCyp links the CypA/CA interaction with the post-
entry restriction mechanism [17,18]. The potent restric-
tion against HIV-1 infection requires the recognition of
HIV-1 CA by the C-terminal CypA domain of TrimCyp. In
addition, the CypA/CA interaction in HIV-1 was shown to
correlate with viral sensitivity to rhesus and African green
monkey Trim5α restriction [19,26,27]. Blocking CypA/
CA interaction by CsA or down-regulating endogenous
CypA by RNAi rescues HIV-1 replication from rhesus and
African green monkey Trim5α restriction, suggesting the
rhesus and African green monkey Trim5α restrict HIV-1
via the CypA-binding pathway. Human Trim5α, on the
other hand, weakly restricts HIV-1 via a pathway that is
independent of CypA binding [26-28]. It is not clear
whether the Trim5α restriction is mediated by direct bind-
ing to CypA or requires an unidentified adaptor protein.
Another explanation is that CypA/CA interaction changes
the CA conformation which provides access for rhesus
and African green monkey but not human Trim5α. We
report here that SIVagmTAN interacts with CypA, but it
has a different recognition pattern by different Trim5α
proteins when compared to HIV-1 [29]. SIVagmTAN is
resistant to the African green monkey Trim5α but suscep-
tible to rhesus Trim5α restriction, whereas HIV-1 is
restricted by rhesus and African green monkey Trim5α via
the CypA-binding pathway. The SIVagmTAN susceptibil-
ity to rhesus Trim5α is probably determined by the patch
on the B30.2 domain and the CypA/CA has little to do
with the restriction [30].
CypA binding is necessary for Trim5α restriction of HIV-1
in rhesus cells, but not for that in human cells. It has been
hypothesized that CypA binding protects HIV from an
unknown restriction factor in humans. If so, then this
hypothesis would have to be extended to account for the
fact that diverse lentiviruses also bind CypA. Our report
here will provide a parallel line to investigate the role that
CypA plays in lentiviral life cycle.
Methods
Cells
293T and CRFK (Crandall Feline Kidney) cells were cul-
tured in Dulbecco's modified Eagle medium with 10%
fetal bovine serum (FBS). Jurkat T cells were grown in
RPMI with 10% FBS. 293T cells were used for generation
of vesicular stomatitis virus G protein (VSV-G) pseudo-
typed lentiviruses and for production of GST-CypA fusion
proteins. CRFK cells expressing TrimCyp protein from dif-
ferent species were generated as described previously [30].
Generation of VSV-G pseudotyped lentiviruses
2.5 × 105 cells/ml of 293T cells were plated in 2 ml/well in
a 6-well plate 16 hours prior to transfection. The VSV-G
pseudotyped HIV-1 WT-GFP, HIV-1 G89V-GFP mutant,
HIV-1 WT-Luc, SIVmac-Luc, and SIVagmTAN-Luc were
generated as described previously [30,31]. Plasimds
pFGinSin and pFP93 [32] used to generate FIV vectors and
virions were gifts of Eric Poeschla (The Mayo Clinic Col-
lege of Medicine, Rochester). For generating VSV-G pseu-
dotyped FIV WT-GFP, 0.75 μg of enhanced green
fluorescent protein transfer vector pFGinSin was co-trans-
fected with 0.4 μg of pL-VSV-G, 0.1 μg of pCMV-tat, and
0.75 μg of pFP93 to 293T cells by FuGene 6 transient
transfection. For generating the VSV-G pseudotyped
mutant FIVs, the same method was applied but replacing
pFP93 with pFP93 proviral DNA with mutations of P84A,
P85A, P88A, P90A, P92A, and R89A. The mutations were
generated with the QuickChange Site-directed mutagene-
sis kit by following the instruction of manufacturer's pro-
tocol (Stratagene). Culture media were collected on 48
hours, 72 hours, and 96 hours after transfection, and were
passed through a 0.2 μm filter (Nalgene) for harvesting
the viruses. FIV P84A-GFP and FIV P90A-GFP were ultra-
centrifuged in an SW28 rotor at 23000 rpm for 1.5 hours
for concentrating viruses 10-fold and 100-fold, respec-
tively. All viruses were aliquoted in 1.5 ml micro-tubes
and frozen at -80°C until use. The FIV viral titer was testedRetrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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Computer modelling of the CA structure from SIVmac and SIVagmTAN Figure 6
Computer modelling of the CA structure from SIVmac and SIVagmTAN. The CA structure from SIVmac and 
SIVagmTAN by using HIV-1 CA crystal structure (PDB:1AK4) as template. The CA from SIVmac (upper panel) and SIVag-
mTAN (lower panel) were superimposed on the CA from HIV-1 which binds to CypA. The proline at position 90 on HIV-1 
CA is indicated.Retrovirology 2006, 3:70 http://www.retrovirology.com/content/3/1/70
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by infecting CRFK cells with different volumes of the orig-
inal viral stocks; the amount of virus causing 20% GFP+
(20% infected cells) was defined as 0.2 CRFK infectious
equivalents.
Infection
CRFK or CRFK cells expressing TrimCyp proteins were
plated 16 hours before infection at a density of 8 × 104
cells/ml on a 12-well (1 ml/well) or a 24-well (0.5 ml/
well) plate. Jurkat T cells for the CypA-dependency exper-
iment were prepared before infection at a density of 2.5 ×
105 cells/ml on a 12-well (1 ml/well) plate. The VSV-G
pseudotyped viruses were added to target cells in the pres-
ence of 20 μg/ml DEAE/Dextran, and spinoculated at
1200 relative centrifugal force (rcf) at room temperature
for 2 hours [33]. The infected cells were placed at 37°C
incubator for 48 hours until the analysis of the infectivity
tested with flow cytometry (for viruses expressing GFP) or
luminometer (for viruses expressing luciferase). The HIV-
1 WT-GFP, HIV-1 G89V-GFP, and all FIVs (WT and
mutants) infected cells was harvested and fixed with 1%
paraformaldehyde for 1 hour at 4°C. The fixed cells were
washed with PBS and re-suspended with 300 μl of PBS
supplemented with 5% calf serum, and subjected to FAC-
Scan (Becton Dickinson) for the analysis of the infectivity.
The HIV-1 WT-Luc, SIVmac-Luc, and SIVagmTAN-Luc
infected cells were washed with PBS and lyzed with 80 μl
of the cell culture lysis buffer (Promega), and 10 μl of the
lysates were used for the measurement of luciferase activ-
ity (infectivity) with the Luciferase assay system
(Promega) and luminometer.
GST-CypA pull down assay
The mRNA from 293T cells were extracted with RNeasy kit
(Qiagen). The human CypA was cloned from the human
mRNA by using the OneStep RT-PCR (Qiagen) with
primer sets 5'-GGATCCACGGTTCAGGTGGTTCTGGAG-
GTTCAGGAGTCAACCCCACCGTGTTC-3' (forward) and
5'-CTCGAGTTATTCGAGTTGTCCACAGTCAGCAATGGT-
3' (reverse). The cyclophilin cDNA was used to replace
huTrim5α in the plasmid pEF/GST-huTrim5α [34] (a
kind gift of Jeremy Luban, Columbia University, New
York). To generate GST-CypA protein in human cells, 1 μg
of pEF/GST-CypA or pEF/GST were transiently transfected
to 293T cells with FuGene 6 (Roche). 72 hours after trans-
fection, one 6-well plate of cells were harvested and lysed
with 1.6 ml of GST buffer (50 mM Tris pH 8.0, 150 mM
NaCl, 0.5% NP40, 0.1% SDS, and supplemented with
complete protease inhibitor). The lysates were centrifuged
at 13200 rpm for 1 minute, and the supernatants were
harvested. To balance the glutathione-sepharose beads
(BD Biosciences) for optimal binding, 200 μl of beads
were centrifuged at 5000 rpm for 5 minutes and washed
with 800 μl of GST buffer for 3 times. The beads were re-
suspended with 200 μl of GST buffer and incubated with
800 μl of GST or GST-CypA supernatants at 4°C on a
slowly rotated shaker for 1 hour. After incubation, beads
were centrifuged at 5000 rpm for 5 minutes and washed
three times with 800 μl of GST buffer. Viruses for the pull
down assay (HIV-1 WT, FIV WT, and FIV mutants) were
prepared by concentrating the same amount of virions
(about 1 ml) into 200 μl of PBS. The concentrated virions
then were incubated with the GST or GST-CypA bound
beads at 4°C on a slowly rotated shaker for 1 hour. Beads
were centrifuged and washed with 800 μl of GST buffer for
3 times. The beads then were re-suspended with 60 μl of
GST buffer and frozen at -80°C until the Western blot
analysis.
Western blot analysis
Lysates from the GST-pull down assay were mixed with 20
μl of sample buffer (2% SDS, 1% 2-mercaptomethanol,
1% glycerol, 65 mM Tris-hydrochloride [34]). 30 μl of the
mixture were loaded on SDS-10% polyacrylamide gels.
After electrophoresis, the proteins were transferred to pol-
yvinylidene difluoride membranes. The membranes were
blocked for 30 minutes at room temperature with 5% fat-
free milk in PBS, and then incubated with a 1:1000 dilu-
tion of a mouse anti-FIV capsid monoclonal antibody
(clone 2C1, from NIH AIDS Research and Reference Rea-
gent program) overnight at 4°C. The membranes were
washed 10 minutes for 3 times in PBS containing 0.1%
Tween 20 and then incubated with a 1:10000 dilution of
a horseradish peroxidase-conjugated anti-mouse mono-
clonal antibody (Santa Cruz Biotechnology) for 30 min-
utes at room temperature. The membranes were washed 3
times for 30 min, and the bound antibody was detected
with the ECL detection system (Amersham).
Sequence alignment and structure computer modeling
Lentiviral Gag sequences were from GenBank. The acces-
sion numbers are: HIV-1 (M19921), HIV-2 (X05291),
SIVcpz (AF115393), SIVmac (AY588946), SIVsm
(AF334679), SIVagmTAN (U58991), and FIV (M25381).
The CA sequences from these lentiviruses were aligned by
the ClustalX software [35,36]. The computer modeling of
N-terminal CA structure from SIVmac and SIVagmTAN
was performed with the SWISS-MODEL server [37, 38, 39]
by using the CA crystal structure of HIV-1 which bound to
human CypA (PDB:1AK4) [4]. The predicted CA struc-
tures were viewed and displayed by DeepView (Swiss Pdb-
Viewer).
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